BAYRY
Bayer AG Spons ADR$12.69 +0.39 (+3.17%)
Oct 26 4:00 PM ET · prev $12.30
Median target
$15.80
+25% · range $15.30–16.68
1 year
+59.2%
from $7.97 · Oct 27
30 days
−12.2%
from $14.46
52-week range
$7.56–15.19
−16% from high · low Nov 3
Avg volume 20D
618.1K
shares / day
Short interest
🔒 Subscribers only
New fund stakes
0
Q2 2026 13F · 0 exits
Congress trades
9
disclosed
Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
No data for this timeframe.
- E Aug 10 Trial readout: Results Pending: Oxymetazoline HCl 0.05% nasal gel (Phase…
- E Aug 11 Trial readout: Results Pending: Oxymetazoline HCl 0.05% nasal gel (Phase…
- X Aug 14 Short interest jumps 26.6% to 661.8K
- E Aug 25 Trial readout: Results Pending: Oxymetazoline HCl 0.05% nasal gel (Phase…
- X Aug 31 Short interest falls 80.8% to 127.3K
- X Sep 15 Short interest jumps 183.4% to 360.8K
- E Sep 23 Trial readout: Results Pending: BAY2599023 (DTX201) (Phase 2) — Completed…
- E Oct 23 Trial readout: Results Pending: BAY2599023 (DTX201) (Phase 2) — Completed…
Signal stack
Where each data set points today.
- InstitutionsMIXED
Q2 2026: 1 added (0 new), 0 trimmed or exited.
- TrendDOWNTREND
6% below its 50-day average.
Who's buying
13F· Q2 20260
new positions
0
exits
| Fund | Move | Value |
|---|---|---|
| First Command Advisory Services, Inc. | DOUBLED | $40.7K |
| PNC FINANCIAL SERVICES GROUP, INC. | DOUBLED | $34.8K |
| KAHN BROTHERS GROUP INC | ADD | $39.6M |
| GREAT LAKES ADVISORS, LLC | ADD | $804.4K |
| RHUMBLINE ADVISERS | ADD | $443.5K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
12-month targets · 4 analysts
$12.69 $15.30 $15.80 $16.68
Price is below the lowest target. Median implies +25%.Targets as of Oct 27, 2026.
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 23, 2026
Trial readout
Results Pending: BAY2599023 (DTX201) (Phase 2) — Completed 38d ago
Trial: Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That…
Oct 8, 2026
Clinical Trial
Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections
Phase 3 · COMPLETED
Oct 5, 2026
Clinical Trial
Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration
Phase 3 · COMPLETED
Sep 29, 2026
Clinical Trial
Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer
Phase 3 · COMPLETED
Sep 23, 2026
Trial readout
Results Pending: BAY2599023 (DTX201) (Phase 2) — Completed 8d ago
Trial: Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That…
Short side
FINRA· Oct 15, 2026🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 23, 2026 Clinical trial readout
Results Pending: BAY2599023 (DTX201) (Phase 2) — Completed 38d ago
Trial: Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment
Jun 30, 2026 Inst.
First Command Advisory Services, — DOUBLED
2,971 shares ($40.7K)
May 29, 2026 Congress
🔒 Fresh data, subscribers only
May 12, 2026 Congress
🔒 Fresh data, subscribers only
Mar 31, 2026 Inst.
PNC FINANCIAL SERVICES GROUP, — DOUBLED
3,030 shares ($34.8K)
Congressional trades
BAYRY trades disclosed by members of Congress, with disclosure delay.
1 members(excl. 2 subscriber-only trades) · 0 buys / 9 sells
| Date | Member | Type | Amount |
|---|---|---|---|
| May 29, 2026 | 🔒 Fresh data, subscribers only | SELL | |
| May 12, 2026 | 🔒 Fresh data, subscribers only | SELL | |
| Apr 23, 2026 | Michael McCaul R· HOUSE· Spouse account· Bayer AG | SELL | $15,001 - $50,000 |
| Apr 15, 2026 | Michael McCaul R· HOUSE· Spouse account· Bayer AG | SELL | $1,001 - $15,000 |
| Apr 8, 2026 | Michael McCaul R· HOUSE· Spouse account· Bayer AG | SELL | $1,001 - $15,000 |
| Mar 17, 2026 | Michael McCaul R· HOUSE· Spouse account· Bayer AG | SELL | $1,001 - $15,000 |
| Feb 17, 2026 | Michael McCaul R· HOUSE· Spouse account· Bayer AG | SELL | $1,001 - $15,000 |
| Feb 6, 2026 | Michael McCaul R· HOUSE· Spouse account· Bayer AG | SELL | $1,001 - $15,000 |
| Feb 5, 2026 | Michael McCaul R· HOUSE· Spouse account· Bayer AG | SELL | $1,001 - $15,000 |